159 related articles for article (PubMed ID: 29477736)
1. Medicare Part D payments for brand and generic drugs prescribed by dermatologists.
Powell HB; Adamson AS
J Am Acad Dermatol; 2018 Sep; 79(3):575-577. PubMed ID: 29477736
[No Abstract] [Full Text] [Related]
2. Medicare Part D payments for neurologist-prescribed drugs.
De Lott LB; Burke JF; Kerber KA; Skolarus LE; Callaghan BC
Neurology; 2016 Apr; 86(16):1491-8. PubMed ID: 27009256
[TBL] [Abstract][Full Text] [Related]
3. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
4. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
[TBL] [Abstract][Full Text] [Related]
5. Ophthalmologist and Optometrist Glaucoma Prescribing Patterns Based on 2015 Medicare Part D Data.
Priluck AZ; Dietze J
Ophthalmol Glaucoma; 2019; 2(1):63-66. PubMed ID: 32672560
[TBL] [Abstract][Full Text] [Related]
6. Industry Payments to Physicians and Prescriptions of Brand-Name Proton-Pump Inhibitors.
Morse E; Fujiwara RJT; Mehra S
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):70-76. PubMed ID: 30325706
[TBL] [Abstract][Full Text] [Related]
7. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States.
Helmuth ME; Liu Q; Turenne MN; Park JM; Oguntimein M; Dutcher SK; Balkrishnan R; Sharma P; Zee J; Leichtman AB; Smith AR
Clin J Am Soc Nephrol; 2019 Mar; 14(3):421-430. PubMed ID: 30819667
[TBL] [Abstract][Full Text] [Related]
8. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D.
de Havenon A; Delic A; Dehoney S; Whetman P; Sheibani N; Callaghan B; Ney J; Esper GJ; Magliocco B; Nair KV
Neurology; 2021 Apr; 96(16):e2132-e2137. PubMed ID: 33692164
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
Duggan M; Morton FS
Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975
[No Abstract] [Full Text] [Related]
10. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
11. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
[TBL] [Abstract][Full Text] [Related]
12. The role of county-level socioeconomic status on brand-name prescriptions in Medicare part D: A cross-sectional Study.
Volpi C; Shehadeh F; Mylonakis E
Medicine (Baltimore); 2020 Feb; 99(9):e19271. PubMed ID: 32118735
[TBL] [Abstract][Full Text] [Related]
13. Variation in cash price of the generic medications most prescribed by dermatologists in pharmacies across the United States.
Alghanem N; Abokwidir M; Fleischer AB; Feldman SR; Alghanem W
J Dermatolog Treat; 2017 Mar; 28(2):119-128. PubMed ID: 27241622
[TBL] [Abstract][Full Text] [Related]
14. Impact of medicare part D plan features on use of generic drugs.
Tang Y; Gellad WF; Men A; Donohue JM
Med Care; 2014 Jun; 52(6):541-8. PubMed ID: 24824538
[TBL] [Abstract][Full Text] [Related]
15. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.
Fleischman W; Agrawal S; King M; Venkatesh AK; Krumholz HM; McKee D; Brown D; Ross JS
BMJ; 2016 Aug; 354():i4189. PubMed ID: 27540015
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the relationship between free drug samples and prescription patterns for acne vulgaris and rosacea.
Hurley MP; Stafford RS; Lane AT
JAMA Dermatol; 2014 May; 150(5):487-93. PubMed ID: 24740450
[TBL] [Abstract][Full Text] [Related]
17. Prescribing trends for biologic drugs among Ohio dermatologists.
Iacullo J; Kunzler E; Ezaldein HH; Scott JF
Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261565
[TBL] [Abstract][Full Text] [Related]
18. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
[TBL] [Abstract][Full Text] [Related]
19. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
20. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
